PDS
Precision Drilling Corporation · Energy
95.02
0.09%(+0.09)
Market OpenLast Updated: — ET
52W L: $36.2052W H: $103.80
$95.19
CHG+3.32 (+3.61%)
H$103.80
L$90.01
VOL2.5M
PDS (1h)
Precision Drilling Corporation · Energy
JPMorgan Chase and Co. grew its holdings in shares of Precision Drilling Corporation (NYSE: PDS) (TSE: PD) by 180.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 37,579 shares of the oil and gas company's stock after acquiring an
CALGARY, Alberta, April 01, 2026 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (Precision or the Company) (TSX:PD; NYSE:PDS) announces today the filing of its Management Information Circular (the Circular) issued in connection with the 2026 Annual Meeting of Shareholders (the Annual Meeting). A copy of the Circular can be downloaded from the Company's SEDAR+ profile at www.sedarplus.ca and the Company's EDGAR Next profile at www.sec.gov . The Circular is also available on Precision's website at www.precisiondrilling.com .
Precision Drilling Corporation (NYSE: PDS - Get Free Report) (TSE: PD) has earned an average rating of "Moderate Buy" from the eight research firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, four have issued a buy rating and
CALGARY, Alberta, March 31, 2026 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (Precision) intends to release its 2026 first quarter results after the market closes on Wednesday, April 29, 2026, and has scheduled a conference call to begin at 11:00 a.m. MT (1:00 p.m. ET) on the next day, Thursday, April 30, 2026.
Filed Phase 3 Amendment Incorporates PFS as Interim Primary Endpoint Expected to Shorten Trial Duration and Reduce Costs
PRINCETON, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call and webcast to report financial results for the quarter and year ended December 31, 2025, and will provide a clinical programs and corporate update, on Monday, March 30, 2026 at 8:00 am Eastern Time.
No recent filings